Trillium Therapeutics Announces Dosing of First Patient in Phase Ib/II Study of TTI-622 in Combination with Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia

Trillium Therapeutics, Inc. announced that it has dosed the first acute myeloid leukemia patient with TTI-622, an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine and venetoclax.